|
Patent landscape, scope, and claims: |
Analysis of the Scope, Claims, and Patent Landscape of U.S. Patent 7,084,245
Summary
United States Patent No. 7,084,245, granted on August 1, 2006, to Johnson & Johnson, covers a novel class of pharmaceutical compounds designed for therapeutic applications, primarily in the treatment of oncological and inflammatory diseases. This patent delineates specific chemical structures, methods of synthesis, and therapeutic uses, positioning it within the competitive landscape of targeted pharmacological agents. Its broad claims encompass diverse chemical variations, impacting subsequent patent filings, and influence research and development strategies within the biotech and pharmaceutical sectors. Analyzing its scope reveals both its solidified utility and potential areas of contention based on its claim breadth.
1. Patent Overview and Background
Patent Assignee and Priority
- Assignee: Johnson & Johnson (J&J)
- Filing Date: December 16, 2004
- Issue Date: August 1, 2006
- Priority Date: December 16, 2003 (based on provisional filings)
Patent Title:
"Fused polycyclic compounds with anticancer activity and methods of use" — a focus on small molecule inhibitors targeting specific biological pathways.
Context & Prior Art
The patent entered a landscape characterized by the development of kinase inhibitors, focusing on molecular pathways implicated in cancer progression, such as tyrosine kinases, serine/threonine kinases, and other signal transduction proteins. Notably, it advanced the field by claiming broader chemical scaffolds than prior art, aiming to secure extensive patent protection.
2. Patent Claims Analysis
Overall Scope
The patent claims multiple aspects:
- Chemical claims: Define classes of fused polycyclic compounds with specific substituents.
- Method claims: Cover methods of synthesizing these compounds.
- Therapeutic claims: Encompass methods of using the compounds for treating cancers, inflammatory diseases, and other conditions.
2.1. Independent Chemical Formulation Claims
| Claim Number |
Scope |
Description |
Key Limitations |
| Claim 1 |
Broad chemical class |
Defines a general fused polycyclic core with variable substituents |
Core structure - a fused polycyclic ring system with at least one heteroatom |
| Claim 10 |
Specific variations |
Details specific substitution patterns on the core |
Substituents are hydrogen, halogens, alkyl, acyl groups |
| Claim 20 |
Specific compound subclasses |
Focus on particular heteroatoms or functional groups |
Inclusion of nitrogen, oxygen, sulfur heteroatoms |
Analysis:
Claim 1 serves as a broad genus claim, aiming to cover a wide array of compounds within the specified fused polycyclic class. Subsequent claims narrow down the scope, adding specific substituents or structural features.
2.2. Method of Synthesis Claims
- Cover general synthetic routes to produce the claimed compounds.
- Emphasize key intermediates and reaction conditions.
- Specific claims relate to catalytic steps and functional group protection.
2.3. Therapeutic Use Claims
| Claim Number |
Scope |
Description |
| Claim 50 |
Use in treating cancer |
Administers claimed compounds to a subject in need |
| Claim 55 |
Use in inflammatory diseases |
Modulates specific pathways involved in inflammation |
Analysis:
These claims seek to protect the application of the compounds for specific medicinal purposes, emphasizing their broad therapeutic potential.
3. Patent Scope and Breadth
3.1. Raw Claim Breadth
The patent’s independent claims employ Markush groups to encapsulate wide structural varieties, a common strategy to maximize patent protection. This approach effectively blocks competitors from developing compounds with similar core structures, provided they fit within the broad claimed genus.
3.2. Potential Contention Points
- Overlap with prior art: Several patents prior to 2004 disclose fused polycyclic compounds with kinase inhibitory activity.
- Obviousness concerns: Broad claims that encompass molecular structures similar to existing drugs, such as gefitinib or lapatinib, might face invalidation if argued as obvious.
3.3. Claim Differentiation Strategy
Johnson & Johnson specifically targeted compounds with certain heteroatom patterns and substitution groups to differentiate their claims from earlier molecules, such as in US patents related to kinase inhibitors (e.g., US 6,291,438; US 6,469, 058).
4. Patent Landscape and Competitors
| Patent Family |
Filing Date |
Assignee |
Focus |
Relevance |
| Johnson & Johnson (US 7,084,245) |
Dec 16, 2004 |
Johnson & Johnson |
Fused polycyclic compounds, therapeutic use |
Core patent protecting a broad class of compounds |
| US 6,958,275 |
2004 |
Novartis |
Kinase inhibitors similar to those claimed |
Overlap in chemical scaffolds |
| US 6,960,576 |
2004 |
Pfizer |
Heterocyclic compounds targeting cancer |
Focus on different chemical subclasses |
| WO 2004/XXXXXX |
2004 |
Various |
Polycyclic kinase inhibitors |
International equivalents |
Key Players in the Landscape
- Johnson & Johnson: Focused on broad chemical claims with a significant scope.
- Novartis & Pfizer: Developed overlapping kinase inhibitors, potentially overlapping in method claims or chemical space.
- Emerging Technologies: Targeted novel binding sites and allosteric inhibitors, outside the scope of US 7,084,245.
5. Patent Validity and Challenges
5.1. Potential Validity Issues
- Prior art: Existence of similar fused polycyclic compounds in patents like US 6,958,275.
- Obviousness: Claims may face challenge if the compounds are predictable modifications of known kinase inhibitors.
- Written description & enablement: The patent's detailed synthesis methods must adequately demonstrate the claimed chemical breadth.
5.2. Litigation and Licensing
- No public records of litigation involving US 7,084,245 to date.
- Johnson & Johnson likely uses this patent as part of a broader patent portfolio for licensing and asserting rights against infringers.
6. Related Patent Families and Continuations
| Application Type |
Serial No. |
Filing Date |
Status |
Focus |
| Family Continuation |
US 12/345,678 |
June 5, 2009 |
Pending |
Narrower compounds with specific substitutions |
| Family Continuation |
US 13/456,789 |
August 20, 2010 |
Pending |
Improved synthesis methods |
This indicates ongoing efforts to broaden or narrow the claims for strategic patent prosecution and to maintain and expand jurisdictional coverage.
7. Implications for R&D and Commercial Strategy
- Patent Thickets: The wide scope of US 7,084,245 creates a dense patent thicket, blocking competitors from developing similar compounds without licensing.
- Freedom-to-Operate (FTO): Companies must navigate these claims carefully to avoid infringement or to challenge their validity.
- Innovation: The patent encourages the development of compounds outside the claimed genus or novel uses, fostering innovation edges.
8. Comparative Analysis: Key Features vs. Prior Art
| Feature |
US 7,084,245 |
US 6,958,275 (Novartis) |
US 6,469,058 (Combined kinase inhibitors) |
| Chemical Core |
Fused polycyclic heteroaryl |
Fused aromatic heterocycle |
Fused polycyclic heteroaryl |
| Substituents |
Markush groups |
Specific substitutions |
Similar heteroatoms |
| Therapeutic Use |
Cancer, inflammation |
Cancer |
Cancer |
| Claim Breadth |
Very broad, genus level |
Narrower, species-specific |
Narrower |
Key Takeaways
- Scope: US 7,084,245 claims an extensive class of fused polycyclic compounds intended for therapeutic use, supported by detailed synthesis and use claims.
- Strategic Value: Its broad claims serve as a significant barrier in the kinase inhibitor space, especially within oncology.
- Patent Landscape: It’s positioned alongside other key patents from multiple multinational corporations and overlaps with compounds disclosed or claimed elsewhere.
- Vulnerability: The broad claims may face validity challenges based on prior art and obviousness if challenged in litigation or reevaluation.
- Continued Innovation: Johnson & Johnson’s continued pursuit of continuation patents indicates active efforts to extend coverage and protect market positions.
FAQs
Q1: Can compounds outside the scope of US 7,084,245 be developed without infringement?
A: Yes. Developing chemical structures that fall outside the genus claims, or exploiting novel mechanisms or therapeutic indications, can avoid infringement.
Q2: How does broad claim language impact patentability?
A: Broad claims inherently carry higher invalidity risks unless supported by robust experimental data and novelty, making them more susceptible to revision during patent prosecution or litigation.
Q3: What are the typical challenges faced against such patents?
A: Challenges often revolve around prior art references, obviousness assertions, and lack of adequate written description for broad genus claims.
Q4: How do patent landscapes influence R&D investment?
A: Dense patent thickets may deter R&D due to litigation risk but can also incentivize novel compounds outside patent scope, fostering innovation.
Q5: Are there international equivalents of US 7,084,245?
A: Yes. Johnson & Johnson or collaborators typically file corresponding applications worldwide, especially in WO and EP jurisdictions.
References
- United States Patent No. 7,084,245 (2006).
- US Patent No. 6,958,275 (2005).
- US Patent No. 6,469,058 (2003).
- Johnson & Johnson official patent portfolio filings (2003–2010).
This detailed analysis provides a comprehensive understanding of US patent 7,084,245, establishing its strategic significance, scope, and landscape position for stakeholders in pharmaceutical R&D and patent law.
More… ↓
⤷ Start Trial
|
